ÂÜÀòÂÒÂ×

experience with early- to late-stage process development programs, contributing to IND-enabling studies, supporting external partnerships and consulting in the cell therapy and AAV gene therapy space. Prior to joining IPS, he strategically led the development of novel AAV manufacturing and analytical platforms through the evaluation of new technologies and continuous process improvement projects. George developed and implemented an AAV process scale-up for transient expression systems in mammalian cells, leveraging DOE yield optimization studies.

His hands-on and consulting experience includes designing and coordinating laboratory expansions and GMP facilities for various cell therapy and AAV process scale-up operations. George is a meticulous, inquisitive, and data-driven leader focused on empowering and developing teams and organizations. He has trained and managed technical staff in AAV process development and production spanning cell thaw to final formulation.